Universidad de Granada Digibug
 

Repositorio Institucional de la Universidad de Granada >
1.-Investigación >
Departamentos, Grupos de Investigación e Institutos >
Departamento de Medicina Legal, Toxicología y Psiquiatría >
DMLTP - Artículos >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/30790

Title: Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistance
Authors: Vera Ramírez, Laura
Sánchez Rovira, Pedro
Ramírez Tortosa, César Luis
Quiles Morales, José Luis
Ramírez Tortosa, María del Carmen
Lorente Acosta, José Antonio
Issue Date: 2013
Abstract: Background Distant recurrences after antineoplastic treatment remain a serious problem for breast cancer clinical management, which threats patients’ life. Systemic therapy is administered to eradicate cancer cells from the organism, both at the site of the primary tumor and at any other potential location. Despite this intervention, a significant proportion of breast cancer patients relapse even many years after their primary tumor has been successfully treated according to current clinical standards, evidencing the existence of a chemoresistant cell subpopulation originating from the primary tumor.
Methods/Findings To identify key molecules and signaling pathways which drive breast cancer chemoresistance we performed gene expression analysis before and after anthracycline and taxane-based chemotherapy and compared the results between different histopathological response groups (good-, mid- and bad-response), established according to the Miller & Payne grading system. Two cohorts of 33 and 73 breast cancer patients receiving neoadjuvant chemotherapy were recruited for whole-genome expression analysis and validation assay, respectively. Identified genes were subjected to a bioinformatic analysis in order to ascertain the molecular function of the proteins they encode and the signaling in which they participate. High throughput technologies identified 65 gene sequences which were over-expressed in all groups (P ≤ 0·05 Bonferroni test). Notably we found that, after chemotherapy, a significant proportion of these genes were over-expressed in the good responders group, making their tumors indistinguishable from those of the bad responders in their expression profile (P ≤ 0.05 Benjamini-Hochgerg`s method).
Conclusions These data identify a set of key molecular pathways selectively up-regulated in post-chemotherapy cancer cells, which may become appropriate targets for the development of future directed therapies against breast cancer.
Sponsorship: Thanks are due to the Consejería de Economia, Innovación y Ciencia (CEIC) from the Junta de Andalucía and Fondo Europeo de Desarrollo Regional (FEDER)/Fondo de Cohesión Europeo (FSE) to financial support through the Programa Operativo FEDER/FSE de Andalucía 2007-2013 and the research project CTS-5350. The authors also acknowledge financial support by the PN de I+D+i 2006-2009/ISCIII/Ministerio de Sanidad, Servicios Sociales e Igualdad (Spain) and Fondo Europeo de Desarrollo Regional (FEDER) from the European Union, through the research project PI06/90388.
Publisher: Public Library of Science (PLOS)
Keywords: Breast cancer
Cancer stem cells
Cancer treatment
Chemotherapy
Gene expression
Gene targeting
Genetic networks
Microarrays
URI: http://hdl.handle.net/10481/30790
ISSN: 1932-6203
Citation: Vera-Ramírez, L.; et al. Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistance. Plos One, 8(1): e53983 (2013). [http://hdl.handle.net/10481/30790]
Appears in Collections:DBBM2 - Artículos
DMLTP - Artículos

Files in This Item:

File Description SizeFormat
VeraRamirez_CancerChemoresistance.pdf1.91 MBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada